Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28017609 | 0.82 | L3MBTL1 (0.33) | KMT2ATHRBL3MBTL1MAPTTRPV1 | |
| SCHEMBL1554553 | 0.82 | MBOAT4 (0.33) | KMT2ATHRBL3MBTL1TRPV1SMN1; SMN2 | |
| SCHEMBL11541379 | 0.81 | ALDH1A1 (0.48) | KMT2AL3MBTL1MAPTTRPV1TSHR | |
| SCHEMBL17157387 | 0.81 | THRB (0.63) | KMT2ATHRBL3MBTL1MAPTNPSR1 | |
| SCHEMBL11536641 | 0.80 | MAPK1 (0.39) | THRBTSHRKIF11KDM4EALDH1A1 | |
| SCHEMBL29480716 | 0.79 | CHRNB2 (0.33) | KMT2ATHRBL3MBTL1MAPTCASP3 | |
| SCHEMBL21436992 | 0.79 | KMT2A (0.34) | KMT2ATHRB | |
| SCHEMBL22735755 | 0.79 | CHRNB2 (0.33) | KMT2ATHRBL3MBTL1MAPTCASP3 | |
| SCHEMBL30831236 | 0.79 | NR1H2 (0.34) | KMT2ATHRBL3MBTL1MAPTCASP3 | |
| SCHEMBL15202873 | 0.79 | NR1H2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093397-B | Compound for treating tumor, synthesis method and application | 自贡市第三人民医院 | 2023-09-05 | — | — | CN | claimed |
| CN-116396336-A | Preparation method and application of difluorophenyl modified aggregation-induced emission iridium complex | 大连理工大学 | 2023-07-07 | — | — | CN | claimed |
| CN-115093397-A | Compound for treating tumor, synthesis method and application | 自贡市第三人民医院 | 2022-09-23 | — | — | CN | claimed |
| WO-2022130403-A1 | NEW QUATERNARY AMMONIUM SALTS FOR TRIFLUOROMETHYLATION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | claimed |
| CN-112500546-B | Preparation method of spherical porous structure two-dimensional covalent organic framework material | 西安理工大学 | 2022-06-07 | — | — | CN | claimed |
| CN-111253443-B | Preparation method and application of electroblotting group modified cyclometalated iridium complex | 大连理工大学 | 2021-10-15 | — | — | CN | claimed |
| CN-112500546-A | Preparation method of spherical porous structure two-dimensional covalent organic framework material | 西安理工大学 | 2021-03-16 | — | — | CN | claimed |
| CN-112321495-A | Preparation method of 2-fluoro-5- (trifluoromethyl) pyridine | 南京麦瑞米生物技术有限公司 | 2021-02-05 | — | — | CN | claimed |
| CN-111253443-A | Preparation method and application of electroblotting group modified cyclometalated iridium complex | 大连理工大学 | 2020-06-09 | — | — | CN | claimed |
| CN-108997202-A | A kind of preparation method of (5- trifluoromethylpyridin -2- base)-acetate | 湖南华腾制药有限公司 | 2018-12-14 | — | — | CN | claimed |
| CN-102892758-B | Pyridine and pyrazine derivatives for the treatment of CF | NOVARTIS AG | 2015-01-07 | — | — | CN | claimed |
| EP-0034917-B1 | 2-SUBSTITUTED-5-TRIFLUOROMETHYLPYRIDINES AND A PROCESS FOR PRODUCING THE SAME | ISHIHARA SANGYO KAISHA LTD. (JP) | 1984-08-08 | — | — | EP | claimed |
| EP-0034917-A1 | 2-Substituted-5-trifluoromethylpyridines and a process for producing the same | ISHIHARA SANGYO KAISHA LTD. (JP) | 1981-09-02 | — | — | EP | claimed |
| JP-56118065-A | — | — | None | — | — | JP | disclosed |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122079263-A | PdBr2Preparation method and application of phosphine derivative thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-0030867-A1 | Process for the preparation of substituted pyridinyloxy ethers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-06-24 | — | — | EP | disclosed |
| US-4266063-A | FROM A HALOPYRIDINE AND HYDROQUINONE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0013145-A2 | Substituted anilinopyridines, processes for their preparation and intermediates for use therein, compositions and herbicidal use thereof | ICI AUSTRALIA LIMITED (AU) | 1980-07-09 | — | — | EP | disclosed |
| EP-0011142-A1 | Pyrido (2,1-b) quinazolinones, their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | MGLL, LIPA, LIPC | KMT2A 2317/4885THRB 2236/4885L3MBTL1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.